Thomas F - Search Results

1

In vivo inhibitory effect of lanreotide (BIM 23014), a new somatostatin analog, on prostaglandin- and cholera toxin-stimulated intestinal fluid in the rat.

Botella A, Vabre F, Fioramonti J, Thomas F, Bueno L. Botella A, et al. Among authors: thomas f. Peptides. 1993 Mar-Apr;14(2):297-301. doi: 10.1016/0196-9781(93)90044-h. Peptides. 1993. PMID: 8097869

2

Lanreotide inhibits human jejunal secretion induced by prostaglandin E1 in healthy volunteers.

Sobhani I, René E, Ramdani A, Bayod F, Sabbagh LC, Thomas F, Mignon M. Sobhani I, et al. Among authors: thomas f. Br J Clin Pharmacol. 1996 Feb;41(2):109-14. doi: 10.1111/j.1365-2125.1996.tb00167.x. Br J Clin Pharmacol. 1996. PMID: 8838436 Free article.

3

Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly.

Heron I, Thomas F, Dero M, Gancel A, Ruiz JM, Schatz B, Kuhn JM. Heron I, et al. Among authors: thomas f. J Clin Endocrinol Metab. 1993 Mar;76(3):721-7. doi: 10.1210/jcem.76.3.8095269. J Clin Endocrinol Metab. 1993. PMID: 8095269

4

Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas.

Gancel A, Vuillermet P, Legrand A, Catus F, Thomas F, Kuhn JM. Gancel A, et al. Among authors: thomas f. Clin Endocrinol (Oxf). 1994 Mar;40(3):421-8. doi: 10.1111/j.1365-2265.1994.tb03941.x. Clin Endocrinol (Oxf). 1994. PMID: 8187308 Clinical Trial.

5

Stimulation of a membrane tyrosine phosphatase activity by somatostatin analogues in rat pancreatic acinar cells.

Colas B, Cambillau C, Buscail L, Zeggari M, Esteve JP, Lautre V, Thomas F, Vaysse N, Susini C. Colas B, et al. Among authors: thomas f. Eur J Biochem. 1992 Aug 1;207(3):1017-24. doi: 10.1111/j.1432-1033.1992.tb17138.x. Eur J Biochem. 1992. PMID: 1499547 Free article.

6

Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers.

Kuhn JM, Legrand A, Ruiz JM, Obach R, De Ronzan J, Thomas F. Kuhn JM, et al. Among authors: thomas f. Br J Clin Pharmacol. 1994 Sep;38(3):213-9. doi: 10.1111/j.1365-2125.1994.tb04344.x. Br J Clin Pharmacol. 1994. PMID: 7826822 Free PMC article. Clinical Trial.

7

A cross-linking assay allows the detection of receptors for the somatostatin analogue, lanreotide in human breast tumours.

Prévost G, Provost P, Sallé V, Lanson M, Thomas F. Prévost G, et al. Among authors: thomas f. Eur J Cancer. 1993;29A(11):1589-92. doi: 10.1016/0959-8049(93)90300-5. Eur J Cancer. 1993. PMID: 8105838

8

Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.

Morange I, De Boisvilliers F, Chanson P, Lucas B, DeWailly D, Catus F, Thomas F, Jaquet P. Morange I, et al. Among authors: thomas f. J Clin Endocrinol Metab. 1994 Jul;79(1):145-51. doi: 10.1210/jcem.79.1.8027218. J Clin Endocrinol Metab. 1994. PMID: 8027218

9

Somatostatin receptors in prostate tissues and derived cell cultures, and the in vitro growth inhibitory effect of BIM-23014 analog.

Tatoud R, Degeorges A, Prévost G, Hoepffner JL, Gauvillé C, Millot G, Thomas F, Calvo F. Tatoud R, et al. Among authors: thomas f. Mol Cell Endocrinol. 1995 Sep 22;113(2):195-204. doi: 10.1016/0303-7207(95)03630-p. Mol Cell Endocrinol. 1995. PMID: 8674827

10

Angiopeptin inhibits oncogene induction in rabbit aorta after balloon denudation.

Bauters C, Van Belle E, Wernert N, Delcayre C, Thomas F, Dupuis B, Lablanche JM, Bertrand ME, Swynghedauw B. Bauters C, et al. Among authors: thomas f. Circulation. 1994 May;89(5):2327-31. doi: 10.1161/01.cir.89.5.2327. Circulation. 1994. PMID: 7910119

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,091 results

Search Page

Filters